Ensign Peak Advisors’s ADMA Biologics ADMA Stock Holding History

Ensign Peak Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$537K	Sell	64,207 -196	-0.3%	-$1.79K	﹤0.01%	965
2026 Q1	$580K	Sell	64,403 -8,018	-11%	-$127K	﹤0.01%	925
2025 Q4	$1.32M	Sell	72,421 -36,819	-34%	-$621K	﹤0.01%	772
2025 Q3	$1.6M	Sell	109,240 -36,772	-25%	-$630K	﹤0.01%	868
2025 Q2	$2.66M	Buy	146,012 +80,462	+123%	+$1.64M	﹤0.01%	816
2025 Q1	$1.3M	Hold	65,550	–	–	﹤0.01%	1108
2024 Q4	$1.12M	Buy	+65,550	New	+$1.23M	﹤0.01%	1249

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ensign Peak Advisors's ADMA Position: Q2 2026 in Review

Ensign Peak Advisors reduced its ADMA Biologics (ADMA) stake by 0.3% in Q2 2026, selling an estimated $1.79K and leaving 64,207 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Ensign Peak Advisors first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.66M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Ensign Peak Advisors held 64,207 shares of ADMA Biologics worth $537K as of Q2 2026.
Ensign Peak Advisors sold 196 ADMA Biologics shares in Q2 2026, an estimated $1.79K.
ADMA Biologics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #965 holding.
Ensign Peak Advisors first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
Ensign Peak Advisors's ADMA Biologics position peaked at $2.66M in Q2 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.